Company profile
Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Zeleciment basivarsen | phase1_2 | — | 1 | active |
| Zeleciment rostudirsen | phase1_2 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07486934 | phase3 | recruiting | 2026-05-14 | 2028-07-01 | Dyne Therapeutics | Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 |
| NCT07608432 | phase3 | recruiting | 2026-06-01 | 2030-12-01 | Dyne Therapeutics | Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) |
| NCT05481879 | phase1_2 | recruiting | 2022-09-05 | 2029-07-01 | Dyne Therapeutics | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 |
| NCT05524883 | phase1_2 | active_not_recruiting | 2022-08-12 | 2031-09-01 | Dyne Therapeutics | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping |
FDA applications (0)
No records yet.